Imlunestrant: First Approval.
Imlunestrant (Inluriyo™), an oral, selective, estrogen receptor (ER) degrader (SERD), is being developed by Eli Lilly and Company for the treatment of ER-positive (ER+), human epidermal growth factor
APA
Keam SJ (2026). Imlunestrant: First Approval.. Drugs, 86(1), 135-141. https://doi.org/10.1007/s40265-025-02266-x
MLA
Keam SJ. "Imlunestrant: First Approval.." Drugs, vol. 86, no. 1, 2026, pp. 135-141.
PMID
41335371
Abstract
Imlunestrant (Inluriyo™), an oral, selective, estrogen receptor (ER) degrader (SERD), is being developed by Eli Lilly and Company for the treatment of ER-positive (ER+), human epidermal growth factor receptor 2 (HER2) negative (HER2-) breast cancer. In September 2025, imlunestrant was approved for the treatment of adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy in the USA. This article summarizes the milestones in the development of imlunestrant leading to this first approval for use in patients with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer.
MeSH Terms
Humans; Breast Neoplasms; Drug Approval; Female; Erb-b2 Receptor Tyrosine Kinases; Estrogen Receptor alpha; United States Food and Drug Administration; United States; Antineoplastic Agents, Hormonal; Receptors, Estrogen; Tamoxifen